Difference between revisions of "Aldesleukin (Proleukin)"
Warner-admin (talk | contribs) m (Text replacement - "[[Bone cancer" to "[[Bone sarcoma") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Bone cancer" to "[[Category:Bone sarcoma") |
||
| Line 28: | Line 28: | ||
[[Category:Cytokines]] | [[Category:Cytokines]] | ||
| − | [[Category:Bone | + | [[Category:Bone sarcoma medications]] |
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
[[Category:Drugs FDA approved in 1992]] | [[Category:Drugs FDA approved in 1992]] | ||
Revision as of 03:32, 24 October 2017
General information
Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Aldesleukin (Proleukin) patient drug information (Chemocare)[4]
- Aldesleukin (Proleukin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 5/5/1992: Initial FDA approval
Also known as
Interleukin-2, IL-2, or Macrolin.